Table 1 Study patients’ characteristics
|
all AML n = 683 |
LOX-low group n = 411, 60% |
LOX-high group n = 272, 40% | p-value | |
|---|---|---|---|---|
|
age at diagnosis median (range) | 46 (16–60) | 47 (16–60) | 50 (18–60) | 0.045 |
| Gender, Female, no. (percent) | 364 (53) | 226 (55) | 138 (51) | 0.276 |
|
Bone marrow blasts at diagnosis [percent] median (range) | 60.5 (3–100) | 63.25 (8–100) | 54.25 (3–96) | < 0.001 |
|
WBC count at diagnosis [Gpt/L] median (range) | 14.5 (0.3–353) | 26.1 (0.3–353) | 6.5 (0.6–243.4) | < 0.001 |
|
Platelet count at diagnosis [Gpt/L] median (range) | 52 (4–1308) | 51 (4–1308) | 52 (4–793) | 0.626 |
|
Serum LDH at diagnosis [U/l] median (range) | 492 (100–7369) | 527 (144–5934) | 389 (100–7369) | < 0.001 |
| FLT3-ITD mutational status positive, no. (percent)a | 167 (25) | 122 (30) | 45 (17) | < 0.001 |
| NPM1 mutational status positive, no. (percent)b | 226 (33) | 155 (38) | 71 (26) | 0.002 |
| Combined NPM1/FLT3 status, no. (percent) | ||||
| NPM1 wt/FLT3 wt | 377 (56) | 204 (50) | 173 (65) | < 0.001 |
| NPM1 wt/FLT3 mut | 70 (10) | 46 (11) | 24 (9) | |
| NPM1 mut/FLT3 wt | 130 (19) | 80 (20) | 50 (19) | |
| NPM1 mut/FLT3 mut | 96 (14) | 75 (18) | 21 (8) | |
| Disease status at diagnosis, no. (percent) | ||||
| De novo AML | 603 (88) | 378 (92) | 225 (83) | 0.001 |
| t-AML | 35 (5) | 17 (4) | 18 (7) | |
| mdsAML | 45 (7) | 16 (4) | 29 (11) | |
| FAB subtypes at diagnosis, no. (percent) | ||||
| M0 | 27 (4) | 11 (3) | 16 (6) | 0.001 |
| M1 | 134 (20) | 96 (23) | 38 (14) | |
| M2 | 204 (30) | 119 (29) | 85 (31) | |
| M4 | 88 (13) | 62 (15) | 26 (10) | |
| M4eo | 36 (5) | 28 (7) | 8 (3) | |
| M5a | 71 (10) | 35 (8) | 36 (13) | |
| M5b | 22 (3) | 11 (3) | 11 (4) | |
| M5 other | 7 (1) | 4 (1) | 4 (1) | |
| M6 | 23 (3) | 9 (2) | 14 (5) | |
| M7 | 6 (1) | 3 (1) | 3 (1) | |
| RAEB | 19 (3) | 9 (2) | 10 (4) | |
| RAEB-T | 33 (5) | 17 (4) | 16 (6) | |
| Cytogenetic subgroups, no. (percent) | ||||
| adverse risk | 157 (23) | 65 (16) | 92 (34) | < 0.001 |
| intermediate risk | 444 (65) | 287 (70) | 157 (58) | |
| favorable risk | 82 (12) | 59 (14) | 23 (8) | |
| Common cytogenetic aberrations, no. (percent) | ||||
| Complex karyotype | 90 (13) | 42 (10) | 48 (18) | 0.005 |
| Normal karyotype | 347 (49) | 242 (59) | 95 (35) | < 0.001 |
| t(8;21) | 39 (6) | 26 (6) | 13 (5) | 0.394 |
| inv16 | 43 (6) | 33 (8) | 10 (4) | 0.022 |
| monosomy 5 | 7 (1) | 3 (1) | 4 (1) | 0.347 |
| del5q | 48 (7) | 20 (5) | 28 (10) | 0.007 |
| monosomy 7 | 30 (4) | 14 (3) | 16 (6) | 0.122 |
| del7q | 20 (3) | 9 (2) | 11 (4) | 0.159 |
| monosomy other than chromosomes 5 or 7 | 43 (6) | 17 (4) | 26 (10) | 0.004 |
| trisomy 8 | 74 (11) | 31 (7) | 43 (16) | 0.001 |
| t(9;11) | 17 (2) | 4 (1) | 13 (5) | 0.002 |
| abnl(11q23) | 59 (9) | 22 (5) | 37 (14) | < 0.001 |
| Extramedullary manifestation of AML, no. (percent) | 59 (9) | 28 (7) | 31 (11) | 0.037 |